EPZM stock forecast
Our latest prediction for Epizyme, Inc.'s stock price was made on the June 13, 2019 when the stock price was at 12.00$.
In the short term (2weeks), EPZM's stock price should underperform the market by 0.00%. During that period the price should oscillate between -8.65% and +10.27%.
In the medium term (3months), EPZM's stock price should outperform the market by 0.38%. During that period the price should oscillate between -19.38% and +28.36%.Get email alerts
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.
At the moment the company generates 30M USD in revenues.
On its last earning announcement, the company reported a loss of -1.62$ per share.
The book value per share is 2.96$
Three months stock forecastJune 13, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|